Alan Sandler, MD is an accomplished leader in oncology and drug development, with experience leading clinical development and operations, regulatory affairs, drug safety and asset development strategy across industry and academia. He is the founder of Sandler Biotech Consulting and serves on the scientific advisory board of Tolremo Therapeutics.
Prior to that, he was the Executive Vice President and Chief Medical Officer of Mirati Therapeutics, a Bristol Myers Squibb Company. Before joining Mirati Therapeutics, Dr. Sandler was President and Global Head of Oncology for Zai Lab, where he led global oncology development for the company. Previously, Dr. Sandler was the Senior Vice President and Global Head, Product Development of Oncology Solid Tumors at Genentech, a member of the Roche Group. He has also held academic roles at Oregon Health and Science University, Indiana University and Vanderbilt University. Dr. Sandler holds an M.D. from Rush Medical College and completed his training in internal medicine and a fellowship in medical oncology at Yale-New Haven Medical Center.
He has published over 300 publications including peer-reviewed articles, reviews, abstracts, and book chapters.